Bone marrow donors sought to grow cells for future therapies

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA RELATED OR THIRD PARTY DONORS (ALLOGENEIC CELLS): * Age greater than or equal to 18 years old * Ability to give informed consent * Adequate clinical parameters (all of the following): * Afebrile (temperature less than 38 (Infinite) C) * Systolic blood pressure greater than 100 \& less than180 mmHg * Diastolic blood pressure greater than 50 \& less than 100 mmHg * Heart rate between 40-100 beats/minute * Females of child-bearing potential must have a negative pregnancy test and one of the following: * Be surgically sterile * Be abstinent until the marrow is collected * Use oral contraceptives, or other form of hormonal birth control * Use an intra-uterine device (IUD) as birth control * Use (by ensuring her male partner(s) use(s) barrier contraception (condom) as birth control INCLUSION CRITERIA AUTOLOGOUS DONORS * Age greater than or equal to 18 years old * Ability to give informed consent * Females of child-bearing potential must have a negative pregnancy test and one of the following: * Be surgically sterile * Be abstinent until the marrow is collected * Use oral contraceptives, or other form of hormonal birth control * Use an intra-uterine device (IUD) as birth control * Use (by ensuring her male partner(s) uses) barrier contraception (condom) as birth control EXCLUSION CRITERIA RELATED OR THIRD PARTY DONORS (ALLOGENEIC CELLS) * Medical history that includes any of the following: * Thrombocytopenia or other blood dyscrasias * Bleeding diathesis * Antibiotic use within the prior 48 hours * History of cancer * History of exposure to transfusion transmitted diseases including HIV and hepatitis B and C as defined by the Standards for Blood Banking and Transfusion Services, American Association of Blood Banks. * Travel to an area where malaria is endemic as defined by the CDC (www.cdc.gov/travel). * At risk for the possible transmission of Creuzefeldt-Jackob Disease (CJD) and Variant Creuzefeldt-Jackob Disease (vCJD) as described in the FDA Guidance for Industry, January 9, 2002, Revised Preventive Measures to Reduce the Possible Risk of Transfusion of Creuzefeldt-Jackob Disease (CJD) and Variant Creuzefeldt-Jackob Disease (vCJD) by Blood and Blood Products * If female, pregnant within the past 6 weeks * Febrile (temperature greater than 38 (Infinite) C) * Systolic blood pressure less than 100 or greater than 180 mmHg * Diastolic blood pressure less than 50 or greater than 100 mmHg * Heart rate less than 40 or greater than 100 beats/minute * Anemia, thrombocytopenia, or leukopenia 1. Hemoglobin level African American women \< 11.5 grams/dL Other women \< 12.0 grams/dL Men \< 12.5 grams/dL 2. HCT African American women \< 34% Other women \< 36% Men \< 38% 3. Platelets less than 150 x 10(3)/microL 4. Absolute neutrophil count less than 1.0 x 10(3)/microL * Prolonged coagulation assays 1. PT greater than 15.2 seconds 2. PTT greater than 37.3 seconds * Positive tests for blood borne pathogens (as required by the Standards for Blood Banks and Transfusion Services, American Association of Blood Banks. The currently required tests include anti-HIV1/2, anti-HCV, Anti-HTVLI/II, anti-T. Cruzi, HBsAg, syphilis, and molecular testing for West Nile virus, HCV and HIV). * Experiencing fever, malaise, anorexia, weight loss or night sweats consistent with active tuberculosis infection EXCLUSION CRITERIA AUTOLOGOUS DONORS -Medical history that includes any of the following: * Currently Pregnant * Positive tests for anti-HIV1/2, anti-HCV, or HBsAg * Active tuberculosis infection